While malignancy is a reasonable differential due to elevated PTHrP, the lack of significant cancer biomarkers, histological samples, imaging findings, and the resolution of hypercalcemia following prednisone therapy make this less likely. This evidence concerns the gene PTHLH and Hypercalcemia.